Investigating the expressions of miRNA-125b and TP53 in endometriosis. Does it underlie cancer-like features of endometriosis? A case-control study by Hajimaqsoudi, Elnaz et al.
International Journal of Reproductive BioMedicine
Volume 18, Issue no. 10, https://doi.org/10.18502/ijrm.v13i10.7767
Production and Hosting by Knowledge E
Research Article
Investigating the expressions of miRNA-125b
and TP53 in endometriosis. Does it underlie
cancer-like features of endometriosis? A
case-control study
Elnaz Hajimaqsoudi1 M.Sc., Farzaneh Darbeheshti2, 3 Ph.D., Seyed Mehdi
Kalantar4 Ph.D., Atiyeh Javaheri5 M.D., Seyed Hamidreza Mirabutalebi4, 6
Ph.D., Mohammad Hasan Sheikhha4 M.D., Ph.D.
1Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences,
Yazd, Iran.
2Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences,
Tehran, Iran.
3Breast Cancer Association (BrCA), Universal Scientific Education and Research Network
(USERN), Tehran, Iran.
4Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University
of Medical Sciences, Yazd, Iran.
5Department of Obstetrics and Gynecology, Faculty of Medicine, Shahid Sadoughi Hospital,
Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
6Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract
Background: Endometriosis is generally considered as a benign condition; however, there is
a possibility for it to become cancerous. miR-125b is upregulated in both endometriotic tissues
and serum samples of women with endometriosis but its potential targets in endometriosis
are still not fully understood.
Objective: The role of miR-125b in the regulation of TP53 expression in endometriosis was
tested with a bioinformatics approach. In addition, the expression of miR-125b and TP53 in
both eutopic (Eu-p) and ectopic endometrium (Ec-p) in the endometrium tissues of women
with endometriosis was compared to those in the normal endometrium tissues of controls
(Normal).
Materials and Methods: In this case-control study, the Eu-p and Ec-p samples were collected
from 20 women who underwent laparoscopic surgery, and the normal endometrium tissues
were collected from 20 controls with no evidence of endometriosis. For bioinformatics
approach, a protein-protein interaction network was constructed based on co-expressed
potential targets of miR-125b. Quantitative polymerase chain reaction technique was used
for the measurement of miR125b and TP53 expression.
Results: Our results showed that miR-125b was significantly overexpressed in Ec-p (p-value:
0.021). In addition, there was a significant TP53 under expression in both the Ec-p and Eu-p
samples compared with the Normal tissues (p-value: 0.003).
Conclusion: The negative correlation between miR-125b and TP53 as well as a noticeable
decreased expression of TP53 in both Ec-p and Eu-p samples may be interpreted as the
roles of miR-125b/TP53 axis in the pathogenesis of endometriosis. In addition, these findings
and bioinformatic analyses imply a possible role of miR-125b in cancer-like features of
endometriosis.
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endometrium.
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1. Introduction
Endometriosis is a common estrogen-
dependent benign disease, characterized by
pelvic pain, dysmenorrhea, and infertility (1). It
occurs when endometrial tissue exists outside
the uterus, and affects 10-15% of women in the
reproductive age (2). Although the underlying
pathogenesis of endometriosis is still not fully
understood, the available body of evidence
indicate that both genetics and environmental
factors contribute to the susceptibility and
progression of endometriosis. While endometriosis
is considered as a benign disorder, some cases
may represent risk factors for developing estrogen-
related malignancies such as ovarian, endometrial,
and breast cancers (3-5). However, other types
of endometriosis-associated cancers have been
rarely reported (6, 7).
Molecular studies have shown a large number
of dysregulated transcripts (both coding and
noncoding) in the ectopic (Ec-p) and eutopic (Eu-
p) endometrial samples from the women with
endometriosis (8-11). miRNAs are highly conserved
21-nucleotide single-stranded noncoding RNAs
that can bind to target mRNAs and regulate their
expression (12). These small noncoding RNAs have
a regulatory function in various cellular processes
such as proliferation, migration, cell cycle, and
apoptosis (13-15). Remarkable dysregulation of
miRNAs in diseases results in using them as
biomarkers for early diagnosis (16). In addition,
miRNAs and their targets can be used for
therapeutic purposes (17).
The dysregulation of miR-125 family, as either
repressors or promoters, has been seen in several
diseases (18). Moreover, a significant upregulation
of miR-125b has been found in endometriosis
and different cancers (19). In one study, mir-125b
in serum samples of women with endometriosis
showed more than 10-fold upregulation compared
with women without endometriosis (20). It has
been suggested that mir-125b plays pivotal role
in molecular pathways driving cell proliferation
and migration that are the crucial steps for
initiating endometriosis and related malignancies
(21, 22).
In this study, the co-expression meta-analysis
of miRNA targets (CoMeTa) database was used to
identify the potential miR-125b targets. After that,
the protein-protein interaction (PPI) network
of co-expressed miR-125b targets revealed
TP53 gene as a hub gene, and showed its
involvement in the functional module. These
pieces of evidence clearly suggest that among
potential miR-125b targets, TP53 has noticeable
roles in cellular processes (Figure 1). It was
reported that miR-125b caused downregulation
of TP53 by binding to a microRNA element in the
3’ untranslated region of TP53 mRNA (23). For
example, it was shown that the overexpression
of miR-125b in human neuroblastoma suppresses
apoptosis by downregulation of TP53. However,
in the contrary, reducing the miR-125b level in
human lung fibroblasts causes overexpression
of TP53 which in turn induces apoptosis
(23).
The most prominent roles of TP53 are cell-cycle
and apoptosis regulation. Previous studies have
shown dysregulation of TP53 in endometriosis
and endometrial cancer (24, 25). In addition,
two associated studies have revealed the link
between TP53 polymorphism and the risk of
endometriosis (26, 27). Interestingly, TP53 has
been validated as a miR-125b target in several
investigations by different methods, including
reporter assay, western blot, and qPCR (23).
However, the dysregulation of miR-125b and TP53
between ectopic and eutopic endometrial samples
has rarely been investigated (28).
Taken together, the relationship between
endometriosis, cancer risk, miR-125b, and TP53
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encouraged us to compare the expression
of both miR-125b and TP53 in three kinds
of samples with each other (Ec-p, Eu-
p, and Normal). In addition, we used the
bioinformatics evidence to investigate that if
TP53, among all the potential miR-125b targets,
has noticeable roles in cellular processes or
not?
Figure 1. (a) Protein-Protein Interaction (PPI) network of predicted miR-125b targets. The size of node is proportional to the node
degree; the node color indicates the betweenness centrality; the width of the edge is proportional to the combined score that
has been obtained from STRING database. (b) The top module from protein-protein interaction network.
2. Materials and Methods
2.1. PPI network construction
In order to provide a comprehensive,
genome-scale analysis of miR-125b regulatory
networks based on its co-expressed targets;
co-expression meta-analysis of miRNA Targets
(CoMeTa) database was used (26). It is
hypothesized that the targets of miR-125b
are co-expressed with each other, and they
belong to the same gene-regulatory network.
In this database, three sequence-based
prediction tools including miRanda, PicTar,
and TargetScan are used. We have kept the
top 100 ranks of co-expressed target genes.
Then, STRING database v10.5 (functional protein
association networks) was run to identify the
protein interactions between them (29). In
the next step, Cytoscape v3.6.1 was applied
to visualize the PPI networks (30). Finally,
the Molecular Complex Detection (MCODE), a
Cytoscape app, was used to identify the module
(31).
2.2. Functional enrichment analysis
The Enrichr web server was applied for
functional annotation of module members based
on GO biological process and GO molecular
function (32). P-value < 0.05 was considered to be
significant enrichment.
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2.3. Sample collection
In this case-control study, the eutopic and
ectopic samples were collected from women
with regular menstrual cycles in the late luteal
phase and referred to the Shahid Sadoughi
Hospital, Yazd, Iran. Case samples were obtained
from endometriosis patients who underwent
laparoscopic surgery. Two biopsies were randomly
removed from the endometriosis tissues (Ec-p,
N = 20), and the endometrium inside the uterus
(Eu-p, N = 20). The diagnosis of endometriosis
in case samples was confirmed by histology in
all women with the disease. The control subjects
(Normal, N = 20) consisted of those women who
had no evidence of endometriosis but were
referred to the hospital for reasons such as
fallopian tube blockage and pelvic pain and in
whom no evidence of pelvic inflammation or
any reproductive system diseases were found
after laparoscopy. The mean age in the case
group was 32 ± 2 yr (20-45 yr) and in the control
group was 36 ± 2 yr (22-43 yr). Women aged
20-45 yr with regular menstrual cycles (28 to 32
days) were included in the study. All samples
were stored in RNase free microtubes containing
RNAlaterTM Stabilization Solution (Thermo Fisher
Scientific) at -80°C for later use. The exclusion
criteria, on the other hand, were hormone therapy
usage within 3 months before surgery, pregnancy,
cancer, and contamination with common DNA
viruses and human papilloma virus as well. Cancer
patients were excluded because we wanted to find
the relation with endometriosis as a cancer-like
features and the genes under study and not the
cancer itself.
2.4. RNA extraction and cDNA
synthesis
The total RNA was extracted from samples
using Trizol reagent (Invitrogen) according to
the manufacturer’s instructions. The ratio of
absorbance at 260 nm and 280 nm (A260/280)
was used to assess RNA purity and quantity
by spectrophotometer. Revert Aid First Strand
cDNA Synthesis Kit (Fermentase, USA) was
applied to synthesize cDNA of mRNA. Additionally,
the Bon-Mir RT kit (Bonyakhteh, Tehran, Iran)
was used to synthesize cDNA of miRNA
based on the manufacturer’s instructions.
The resultant cDNA mixtures were stored at
-20°C.
2.5. Gene expression study
Real-time PCR was performed using the
commercial master mix (Takara, Japan).
The sequences of primers were: SNORD
forward 5’-ATCACTGTAAAACCGTTCCA-3’,
miR-125b forward primer as well as universal
reverse primers for both miR-125b and
SNORD were obtained from Bonyakhteh
(Bonyakhteh, Tehran, Iran), TP53 forward
5’-GCTCAGATAGCGATGGTCTGG-3’, TP53
reverse 5’-CTGTCATCCAAATACTCCACACG-
3’, GAPDH forward 5’-
CTCATTTCCTGGTATGACAACGA-3’, GAPDH
reverse 5’-TCTTCCTCTTGTGCTCTTGCTG-3’.
Moreover, the miR-125b and TP53 expression
levels were normalized by SNORD and GAPDH
expression, respectively. Reaction mixture
included 2 μl cDNA templates, 0.5 μl forward
and reverse primers, 7 μl ribonuclease-free water,
and 10 μl commercial master mix for a final
reaction volume of 20 μl. The thermal cycling
conditions were initiated with denaturation
at 95°C for 10 min, and then 40 cycles at
95°C for 15 sec, and annealing at 60°C for
20 sec. For miR-125b detection, the real-
time PCR profile was as described earlier,
except for a melting temperature of 57°C.
Each reaction was performed in duplicate, and
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expression levels were evaluated using two
(−Δct).
2.6. Cancer-related pathway analysis
of miR-125b
DIANA miRPath was run to miR-125b pathway
analysis based on experimentally validated
miRNA interactions derived from TarBase
database (33). Cancer-related KEGG pathways
were extracted and visualized by Cytoscape
software.
2.7. Ethical consideration
This study was approved by the ethics
committee of Yazd Reproductive Sciences Institute,
Shahid Sadoughi University of Medical Science,
Yazd, Iran (code: IR.SSU.MEDICIN.REC.1396.151)
and written informed consents were obtained from
all individuals.
2.8. Statistical analysis
Statistical calculations were performed using
the SPSS (Statistical Package for the Social
Sciences, version 21.0, SPSS Inc, Chicago,
Illinois, USA) software. Data were presented
with mean and 95% CI. Kruskal-Wallis ANOVA
was applied to analyze miR-125b or TP53
expression among case-eutopic, case-ectopic,
and control tissues. Mann-Whitney U-test was
used to analyze expression between two groups.
Data were considered significant when p < 0.05
was obtained. The Pearson’s correlation statistic
was used to evaluate the linear correlation
between TP53 and miR-125b expression. The
linear regression model was applied to evaluate
the linear effect of miR-125b expression on TP53
expression.
3. Results
3.1. PPI network of predicted miR-125b
targets
CoMeTa data were used to provide miR-125b
regulatory network based on its co-expressed
targets. PPI network has been constructed
for potential miR-125b targets, which are co-
expressed by STRING database. STRING outputs
were further visualized using Cytoscape (Figure
1a). TP53 with the highest degree (the number
of incoming and outgoing edges) and between
centrality (a measure of centrality in a graph
based on shortest paths) was selected as
a hub gene. After that, the top module was
extracted by MCODE. The results showed that
TP53 gene is included in the top module (Figure
1b).
3.2. Functional enrichment analysis of
module
All the module members were uploaded
into the online Enrichr database to investigate
the GO categories. The results revealed
that module members are significantly
enriched in cell proliferation, apoptosis,
cell migration, and cell signaling (Table
I).
3.3. miR125b and TP53 expression in
endometriosis
The analysis of miR125b and TP53 expression
in Eu-p and Ec-p as well as Normal tissues by
Kruskal-Wallis test indicated that both miR125b
(p = 0.024) and TP53 (p = 0.003) expression were
significantly different between cases (Eu-p and
Ec-p) and Normal control samples. miR-125b in
the Ec-p and TP53 in the Normal control tissues
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had the highest expression levels. In addition,
Mann-Whitney test outputs revealed that miR-125b
expression was significantly different between the
Eu-p and Ec-p tissues (p = 0.015) as well as
between the Ec-p and Normal control tissues
(p = 0.021). Concerning TP53 expression, Mann-
Whitney test indicated that its expression was
significantly different between the Eu-p andNormal
control tissues (P-value = 0.03) as well as between
the Ec-p and Normal control tissues (p = 0.001)
(Figure 2).
3.4. Correlation between TP53 and
miR-125b expression
A negative correlation was seen between
the expression of the two targeted genes
(r = -0.2, p = 0.04) among all samples (Figure
3). The linear regression model revealed that
for every 1 unit additional miR-125b expression
in samples, we would expect to see a 0.14-
unit decreseas in the TP53 expression (Figure
2).
3.5. Cancer-related KEGG pathways of
miR-125b
DIANA miRPath database revealed
that miR-125b has several experimentally
validated target genes, which are involved
in cancer-related KEGG pathways, such as
endometrial and ovarian cancers. Among the
miR-125b-validated targets, TP53 is associated
with more cancer-related pathways (Figure
3).
Table I. Functional enrichment analysis of module members according to the online Enrichr database based on GO biological
process and GO molecular function
Ontologies Gene ontology term P-value
GO biological process 2018
Mammary gland development 0030879 0.00004
Positive regulation of cell migration involved in sprouting angiogenesis 0090050 0.000001
ERBB2 signaling pathway 0038128 0.00002
Negative regulation of programmed cell death 0043069 0.00001
Negative regulation of apoptotic process 0043066 0.00001
Regulation of cell population proliferation 0042127 0.0001
Positive regulation of cell migration by vascular endothelial growth factor
signaling pathway
0038089 0.002
Positive regulation of vascular endothelial cell proliferation 1905564 0.003
GO molecular function 2018
Growth factor receptor binding 0070851 0.00003
Epidermal growth factor receptor binding 0005154 0.0003
Mitogen-activated protein kinase kinase binding 0031434 0.0003
Vascular endothelial growth factor receptor binding 0005172 0.003
Vascular endothelial growth factor receptor 2 binding 0043184 0.002
Fisher’s exact test was used. GO: Gene ontology ERBB2: Erb-B2 Receptor Tyrosine Kinase 2
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Figure 2. Differences in expression among Eu-p, Ec-p, and Normal control samples; a) miR-125b, SNORD. b) TP53 GAPDH (Error
Bars: 95% CI).















Figure 3. Association between TP53 and miR-125b expression in all samples (n = 60, r = -0.26. p = 0.04). Regression equation by
linear regression analysis.
4. Discussion
Endometriosis is a common chronic disease and
affects about 10-15% of women of reproductive
age. This disease is characterized by the growth
of endometriotic tissue outside the uterine.
Although endometriosis is generally considered
as a benign condition, it shows a risk for
transformation and becoming cancerous (34).
miRNAs, as a non-coding regulatory RNAs, are
involved in post-transcriptional gene regulation.
Dysregulation of miRNAs in endometriosis and
cancers have been reported in the previous
studies (35, 36). Hawkins and colleagues have
shown several upregulated and downregulated
miRNAs in endometriomas compared with
the normal endometrium (37). Also, Ohlsson
Teague and co-workers have found dysregulated
miRNAs between pairs of ectopic and eutopic
endometrial tissues (19). These investigations
indicate the roles of miRNAs in the development
of endometriosis.
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Phenotypic resemblance between
endometriotic and malignant cells such as
uncontrolled cell growth and decreased apoptosis
indicates their common molecular features. In
addition, it is suggested that miRNAs and their
targets can be considered as effectors in both
endometriosis and endometriosis-associated
cancers. The identification of dysregulated
miRNAs and their targets in the eutopic and
ectopic endometrium is an essential step
toward understanding molecular links between
endometriosis and cancers. Moreover, this
information can be useful for developing
therapeutic strategies. In the current study,
in the first step, we selected miR-125b and
investigated its potential targets with bioinformatic
approach. In the previous studies, miR-125b
had shown a significant upregulation in both
endometriotic tissues and serum samples of
women with endometriosis (19, 20). In addition,
the role of this microRNA as an oncomiR have
been reported in cancers. Zhou and co-authors
indicated that mir-125b acts as an apoptosis
suppressor in breast cancers (38). Furthermore,
Bousquet and colleagues suggested that miR-125b
confers a proliferative advantage to the leukemic
cells (39). Similarly, Xia et al demonstrated that
overexpression of miR-125b promotes human
glioma cell proliferation (40).
Here, miR-125b regulatory network was
investigated and PPI network was constructed
based on its co-expressed potential targets.
These analyses indicate that TP53 is a remarkable
potential target for miR-125b. Moreover, the top
module in the PPI network includes TP53 protein
(Figure 1). Module-based functional pathway
enrichment analysis has revealed roles of TP53
and other members of module in different cancer-
related pathways such as regulations of cell
migration, of vascular endothelial cell proliferation,
and of apoptotic process (Table I). As far as
the association between endometriosis and
cancer is concerned, our bioinformatic analyses
point out that TP53 is a potential appropriate
target for miR-125b. Interestingly, the interaction
between miR-125b and TP53 miRNA has been
validated in human neuroblastoma, myeloid,
and cardiac fibroblasts cells (23, 41, 42). It is
shown that the loss of miR-125b during zebrafish
embryogenesis leads to aberrant apoptosis
due to overexpression of TP53. Jiang and
colleagues proposed that miR-125b inhibits
TP53 network activity by regulating the dose
of both proliferative and apoptotic regulators
(43). In the present study, the expression of
miR-125b and TP53 in eutopic and ectopic
endometrium of women with endometriosis as
well as normal control tissues were explored.
Our results revealed a negative correlation
between miR-125b and TP53 expression in the
three types of samples. These findings suggest
that miR-125b regulates TP53 expression in
endometrium. The ectopic tissues showed the
highest expression of miR-125b and the lowest
expression of TP53.
Furthermore, several studies have reported
inhibitory roles of TP53 in cell invasion and
metastasis (44, 45). This finding can explain the
characteristics of ectopic endometrium such
as greater ability of migration and invasion
compared with eutopic endometrium (46). Our
data demonstrated that expression of both miR-
125b and TP53 is significantly different between
ectopic endometrium and normal control samples.
Moreover, while there was no overexpression
of miR-125b in eutopic samples, it significantly
showed low expression of TP53 compared
with normal samples. This could be due to an
overexpression of miR-125b in Ec-P samples and
its effect on all of the patient’s tissues including Eu-
p tissues. Consistently, Allavena and co-workers
showed that the expression of TP53 decreases
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in the ectopic endometrium of patients compared
with eutopic and normal samples (25).
Our results, consistent with previous studies,
revealed that TP53 expression decreases in
benign endometriotic cysts compared with normal
controls. This observation can suggest that
alterations in the TP53 expression, as a tumor
suppressor gene, may be involved in the same
molecular features between endometriosis and
cancers. Our results, according to previous studies,
demonstrates the existence of negative correlation
between the expression of miR-125b and TP53
in both the case and control samples (Figure
3).
Finally, in order to investigate the potential
roles of miR-125b in endometriosis-associated
cancers, we constructed cancer-related KEGG
pathways of validated targets of miR-125b. Among
the miR-125b-validated targets, such as TP53,
STAT3, E2F3, CDKN2A, AKT1, and ERBB2, TP53
shows association with more cancer-related
pathways (Figure 4). A combination of this
analysis and our experimental data indicates
multiple roles of miR-125b, which may underlie
endometriosis-associated cancers. However, since
both tumor suppressor genes and oncogenes
are seen among validated targets of miR-125b,
it is proposed that miR-125b has an opposing
function as an oncogene and a tumor suppressor
in different cell contexts. Further studies are
necessary for investigating the association
between miR125b expression and developing
endometriosis-associated cancers in women with
endometriosis.
Figure 4. Cancer-related KEGG pathways of miR-125b. The blue nodes represent experimentally validated targets of miR-125b.
The green nodes represent cancer-related KEGG pathways. The size of blue node is proportional to the node degree. Data were
obtained from DIANA-miRPath database.
5. Conclusion
In conclusion, the negative correlation between
miR-125b and TP53 as well as the noticeable
decreased expression of TP53 in both eutopic and
ectopic samples compared with Normal controls
may be interpreted in roles of miR-125b/TP53
axis in the pathogenesis of endometriosis.
In addition, these finding and bioinformatics
analyses imply a possible role of miR-125b in the
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connection between endometriosis and malignant
transformation.
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